Knott David M Jr Makes New $1.12 Million Investment in Atyr PHARMA INC (NASDAQ:ATYR)

Knott David M Jr acquired a new stake in shares of Atyr PHARMA INC (NASDAQ:ATYR) in the fourth quarter, Holdings Channel.com reports. The firm acquired 308,133 shares of the company’s stock, valued at approximately $1,115,000. Atyr PHARMA makes up about 0.4% of Knott David M Jr’s investment portfolio, making the stock its 28th largest position.

Other hedge funds have also made changes to their positions in the company. Victory Capital Management Inc. bought a new stake in shares of Atyr PHARMA during the fourth quarter valued at approximately $37,000. D.A. Davidson & CO. bought a new position in Atyr PHARMA in the fourth quarter worth $141,000. JPMorgan Chase & Co. boosted its stake in Atyr PHARMA by 52.0% during the third quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock worth $55,000 after buying an additional 10,754 shares in the last quarter. Farther Finance Advisors LLC bought a new stake in Atyr PHARMA in the 4th quarter valued at $88,000. Finally, Alterna Wealth Management Inc. acquired a new position in shares of Atyr PHARMA in the 4th quarter valued at $36,000. Institutional investors own 61.72% of the company’s stock.

Atyr PHARMA Stock Down 3.5 %

NASDAQ ATYR opened at $3.02 on Tuesday. The stock’s 50 day simple moving average is $3.64 and its 200 day simple moving average is $3.21. Atyr PHARMA INC has a one year low of $1.42 and a one year high of $4.66. The firm has a market cap of $268.35 million, a PE ratio of -3.21 and a beta of 0.98. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41.

Atyr PHARMA (NASDAQ:ATYR) last released its earnings results on Thursday, March 13th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05. As a group, sell-side analysts forecast that Atyr PHARMA INC will post -0.91 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Cantor Fitzgerald started coverage on shares of Atyr PHARMA in a research note on Monday, January 6th. They issued an “overweight” rating on the stock. Leerink Partners initiated coverage on Atyr PHARMA in a research note on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 price objective on the stock. Leerink Partnrs upgraded Atyr PHARMA to a “strong-buy” rating in a research report on Tuesday, February 18th. Finally, HC Wainwright reiterated a “buy” rating and issued a $35.00 price target on shares of Atyr PHARMA in a research report on Friday, March 14th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $18.60.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.